Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Tissue TMB Disappoints as Treatment Response Biomarker in NSCLC
Key clinical point: Tissue tumor mutational burden was not significantly associated with treatment efficacy in the KEYNOTE-189 and -021 studies.
Major finding: Pembrolizumab plus chemo improved overall survival both in patients with TMB of 175 mutations/exome and greater and in those with less TMB of less than 175 mutations/exome (hazard ratio for OS, 0.64 for both).
Study details: Analysis of data from KEYNOTE-189 and -021 in 293 and 70 patients, respectively.
Disclosures: Both KEYNOTE-189 and KEYNOTE-021 were supported by Merck. Dr. Garassino and Dr. Langer reported relationships with several pharmaceutical companies.